Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
about
Distinct gene expression profiles in peripheral blood mononuclear cells from patients infected with vaccinia virus, yellow fever 17D virus, or upper respiratory infectionsEvaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever VirusHost sexual dimorphism and parasite adaptationDescription of a prospective 17DD yellow fever vaccine cohort in Recife, Brazil.How sex and age affect immune responses, susceptibility to infections, and response to vaccinationImmunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and MaliImpact of Fighting on Antibody Response to Hepatitis B Virus Vaccine in Mice.A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213/77 in children nine-23 months oldEfficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.Current status and future prospects of yellow fever vaccines.The early-onset febrile reaction following vaccination and associated factors: An exploratory sub-study based on the Ebola vaccine clinical trial.A Meta-Analysis of Serological Response Associated with Yellow Fever Vaccination.Early molecular correlates of adverse events following yellow fever vaccination.
P2860
Q27485174-215C5130-AF67-4C21-9040-49832E3F20B7Q27485366-238658CC-E51B-42C5-A18A-B1DD066E9144Q28731656-613F8F63-245C-42D7-82A1-C1B18EA3E8A0Q35246149-7B1FA69F-D118-42E1-AA31-C0D42C55F0F9Q35527150-5ADA52BD-2965-4FFA-B250-96A163494CD4Q36265085-E011A46D-638C-4974-A767-FED9FD6553A1Q36274406-346010D4-0812-4E36-8FF2-2A634146C3BBQ36341250-3FF55F12-F57C-46FF-9447-C08B49EDB4ABQ37166091-EEB6C10C-8C44-4031-97D2-B7CA4AB150E1Q38586294-EE918799-00F2-4801-82BB-8FB490C2D534Q38865003-1E17610E-B519-4904-A1EB-98FEBB8FF032Q39032355-4D7EBCBE-2DB1-4C45-A793-4F748DE6B2D4Q41928069-7AC9AF1C-EE73-45D7-BD7B-223295542B9D
P2860
Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Immunogenicity and safety of B ...... s in a phase 3 clinical trial.
@en
type
label
Immunogenicity and safety of B ...... s in a phase 3 clinical trial.
@en
prefLabel
Immunogenicity and safety of B ...... s in a phase 3 clinical trial.
@en
P2093
P1476
Immunogenicity and safety of B ...... es in a phase 3 clinical trial
@en
P2093
Abdallah Ennaji
Achim Kaufhold
Didier Favre
Helene Hilfiker
Johanna L'Age-Stehr
Markus Pfister
Oliver Kürsteiner
Peter Durrer
P304
P356
10.4269/AJTMH.2005.72.339
P407
P50
P577
2005-03-01T00:00:00Z